Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

Form 4	MACEUTICAL	5 INC	Ū								
May 11, 2012 FORM Check this if no longe subject to Section 16 Form 4 or Form 5 obligations may contin <i>See</i> Instruct 1(b).	4 UNITED S	ENT OI uant to S) of the I	Was F CHAN Section 16	hington, GES IN I SECURI 5(a) of the ility Hold	D.C. 209 BENEFI ITIES Securiti ing Com	549 CIA les Ez ipany	L OW schang	COMMISSION NERSHIP OF ge Act of 1934, f 1935 or Sectio 40	OMB Number: Expires: Estimated a burden hou response	irs per	
(Print or Type Re	esponses)										
1. Name and Address of Reporting Person <u>*</u> CAROTA MARK			2. Issuer Name and Ticker or Trading Symbol DUSA PHARMACEUTICALS INC [DUSA]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O DUSA P INC., 25 UP1	PHARAMCEUTI	iddle) CALS,	3. Date of (Month/Da 05/09/20	-	ansaction			Director X Officer (give below) Vice Pre		6 Owner er (specify ions	
WILMINGT		4. If Amendment, Date Original Filed(Month/Day/Year)					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 				
(City)	(State) (Z	Zip)	Table	e I - Non-De	erivative S	Securi	ties Acq	uired, Disposed o	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Executio any		3. Transactic Code (Instr. 8) Code V		spose	d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	05/09/2012			F	872 <u>(1)</u>	D	\$ 6.13	188,285 <u>(2)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

De Se	Title of erivative ecurity nstr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
					Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
CAROTA MARK C/O DUSA PHARAMCEUTICALS, INC. 25 UPTON DRIVE WILMINGTON, MA 01887			Vice President, Operations					
Signatures								
/s/ Mark Carota 05/11/2012								

/s/ Mark Carota 05/11/2012

**Signature of Reporting Person Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These shares represent payment of withholding tax liability incident to the vesting of restricted stock granted May 9, 2008.
- Includes Stock Awards which vest at the rate of one-quarter of the total grant on each of the first, second, third and fourth anniversaries of (2)the date of the grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.